[CAS NO. 171235-71-5]  TAPI-1

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [171235-71-5]

Catalog
SLK-S7434
Brand
Selleck
CAS
171235-71-5

DESCRIPTION [171235-71-5]

Overview

MDL-
Molecular Weight499.60
Molecular FormulaC26H37N5O5
SMILESCC(C)CC(CC(=O)NO)C(=O)NC(CC1=CC2=CC=CC=C2C=C1)C(=O)NC(C)C(=O)NCCN

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.0016 mL10.0080 mL20.0160 mL
5 mM0.4003 mL2.0016 mL4.0032 mL
10 mM0.2002 mL1.0008 mL2.0016 mL
50 mM0.0400 mL0.2002 mL0.4003 mL

Description

TAPI-1 is an inhibitor, which blocks shedding of cytokine receptors. TAPI-1 is also an inhibitor of .

Targets

ADAM17/TACE [1]MMP [5]

In vitro

TAPI-1 prevents unstimulated and PMA-induced release of the soluble forms of TNF-alpha, p60 TNFR, and IL-6R from the monocytic cell line, THP-1, and from human peripheral blood monocytes. TAPI also inhibits LPS-induced shedding of the p60 TNFR and TNF-alpha from monocytes. TAPI-1 inhibits TACE-dependent constitutive release of co-transfected APP(695). TAPI-1 attenuates Ang II-induced EGFR transactivation and cell proliferation in human HSC line LI90. TAPI-1 with the EGFR inhibitor AG1478 exhibits deactivated AREG/EGFR/ERK signaling pathway and reduces pro-inflammatory cytokines release in pSS salivary gland-derived epithelial cells.